This document provides general medical information for educational purposes only and should not be considered as medical advice. It is not a substitute for professional medical judgment, diagnosis, or treatment. Clinicians must exercise their independent medical judgment in the context of individual patient care. Always consult with a qualified healthcare professional for any health concerns or before making any decisions related to patient care. Information presented here may not be exhaustive, and medical knowledge and guidelines evolve.

---

Approach To Myelopathy

Overview

Definition

Myelopathy refers to a neurological deficit resulting from dysfunction of the spinal cord. It is characterized by signs and symptoms localized to the spinal cord tracts, manifesting as motor, sensory, or autonomic disturbances below the level of the lesion. It is distinct from radiculopathy, which involves compression or irritation of a nerve root, typically causing pain and deficits in a dermatomal/myotomal distribution without upper motor neuron signs.

Epidemiology

The epidemiology of myelopathy is largely dependent on its underlying etiology: * Cervical Spondylotic Myelopathy (CSM) is the most common cause of spinal cord dysfunction in adults, affecting an estimated 1-2% of the general population over 50 years, with increasing prevalence in older age groups. * Acute Transverse Myelitis (ATM) has an estimated incidence of 1-4 per million people per year, affecting all age groups, but with peaks in childhood and young adulthood. * Spinal cord injury (SCI) has an annual incidence of approximately 17,900 new cases in the United States, predominantly affecting young males (median age 43). * Other causes like vitamin deficiencies, vascular myelopathy, and tumors have varying, generally lower, incidences.

Classification

Myelopathy can be classified based on several factors:

• By Onset and Progression:
  • Acute Myelopathy: Develops over minutes to hours (e.g., spinal cord infarct, trauma).
  • Subacute Myelopathy: Develops over days to weeks (e.g., transverse myelitis, epidural abscess, vitamin B12 deficiency).
  • Chronic Myelopathy: Develops over months to years (e.g., cervical spondylotic myelopathy, multiple sclerosis).
• By Etiology:
  • Compressive Myelopathy: Caused by extrinsic compression of the spinal cord (e.g., disc herniation, spinal stenosis, tumor, epidural hematoma/abscess).
  • Non-Compressive Myelopathy:
    • Inflammatory/Autoimmune: Transverse myelitis, multiple sclerosis (MS), neuromyelitis optica spectrum disorder (NMOSD), sarcoidosis, lupus myelitis.
    • Vascular: Spinal cord infarction, dural arteriovenous fistula (DAVF), epidural/subdural hemorrhage.
    • Infectious: HIV, HTLV-1, syphilis, Lyme disease, viral (herpes zoster, enteroviruses), bacterial (tuberculosis, epidural abscess).
    • Nutritional/Metabolic: Vitamin B12 deficiency (subacute combined degeneration), copper deficiency, organophosphates.
    • Toxic: Chemotherapeutic agents, illicit drugs.
    • Genetic/Hereditary: Hereditary spastic paraparesis, spinocerebellar ataxias.
    • Radiation Myelopathy: Delayed complication of radiation therapy.
    • Paraneoplastic: Associated with systemic malignancy.
• By Location:
  • Cervical Myelopathy: Lesion in the cervical spinal cord.
  • Thoracic Myelopathy: Lesion in the thoracic spinal cord.
  • Lumbar Myelopathy (Conus Medullaris Syndrome): Lesion at the terminal end of the spinal cord (L1-L2 vertebral level). Cauda equina syndrome, while presenting with similar symptoms, involves nerve roots and is distinct from myelopathy.

Pathophysiology

Mechanism

Myelopathy results from damage to the ascending (sensory) and descending (motor) tracts within the spinal cord, or to the spinal cord parenchyma itself. The specific mechanisms vary by etiology:

• Compression: Mechanical pressure on the spinal cord (e.g., from disc herniation, osteophytes, tumors) directly distorts neural tissue and can compromise blood supply (ischemia) by compressing radicular arteries or the anterior spinal artery. This leads to demyelination, axonal injury, and neuronal loss.
• Inflammation/Demyelination: Immune-mediated attacks (e.g., in MS, NMOSD, transverse myelitis) target myelin, axons, or oligodendrocytes, disrupting nerve impulse conduction. Inflammatory edema also contributes to cord dysfunction.
• Ischemia: Insufficient blood supply to the spinal cord (e.g., spinal cord infarction due to aortic dissection, severe atherosclerosis, vasculitis, or DAVF) leads to neuronal and axonal death. The anterior spinal artery supplies the anterior two-thirds of the cord, making it particularly vulnerable to infarction.
• Nutritional Deficiencies: Lack of essential nutrients (e.g., vitamin B12, copper) impairs myelin synthesis and maintenance, leading to demyelination and axonal degeneration (e.g., subacute combined degeneration).
• Infection: Direct invasion of the spinal cord by pathogens (e.g., viruses) or indirect effects of inflammation/abscess formation can cause cord damage.
• Toxicity: Certain chemicals or drugs can directly injure spinal cord neurons or myelin.
• Radiation: Delayed effects of high-dose radiation can cause demyelination, gliosis, and vascular changes in the spinal cord.

Risk Factors

• Age: Increased risk of degenerative causes like CSM.
• Spinal Stenosis: Pre-existing narrowing of the spinal canal.
• Trauma: Acute spinal cord injury from falls, motor vehicle accidents, violence.
• Autoimmune Diseases: Systemic lupus erythematosus, Sjögren's syndrome, rheumatoid arthritis, MS, NMOSD.
• Infections: HIV, HTLV-1, syphilis, tuberculosis.
• Vascular Disease: Atherosclerosis, hypertension, diabetes, aortic surgery (risk for spinal cord infarction).
• Nutritional Deficiencies: Malabsorption (e.g., post-gastrectomy, Crohn's disease), strict vegan diet without supplementation (B12 deficiency), zinc supplementation (copper deficiency).
• Cancer: Primary spinal cord tumors, metastatic disease, paraneoplastic syndromes.
• Radiation Therapy: Previous radiation to the spine.
• Genetic Predisposition: For certain hereditary myelopathies.

Protective Factors

Specific protective factors for myelopathy itself are limited. Instead, prevention focuses on mitigating risk factors and early intervention: * Maintaining Spinal Health: Proper posture, regular exercise, ergonomic practices to reduce spinal strain. * Management of Chronic Diseases: Strict control of hypertension, diabetes, and hyperlipidemia to reduce vascular risk. * Nutritional Sufficiency: Adequate intake of vitamins, particularly B12. Supplementation for those at risk (e.g., vegans, post-gastrectomy patients). * Early Diagnosis and Treatment: Prompt identification and management of autoimmune conditions, infections, and tumors can prevent or minimize spinal cord damage. * Injury Prevention: Safety measures to prevent falls and traumatic spinal injuries.

Clinical Presentation

Signs and Symptoms

The presentation of myelopathy depends on the level and extent of spinal cord involvement. Symptoms are typically bilateral, although they can be asymmetric, and localize below the level of the lesion.

Cardinal Features

• Motor Dysfunction:
  • Weakness: Progressive spastic weakness (paresis or paralysis) in limbs, often more pronounced distally.
  • Spasticity: Increased muscle tone, clonus, muscle spasms.
  • Gait Disturbance: Spastic gait (stiff-legged, scissoring) or ataxic gait (unsteady, broad-based) due to sensory loss.
• Sensory Dysfunction:
  • Numbness, Tingling, Paresthesias: Often bilateral, in a "glove-and-stocking" distribution or with a distinct sensory level.
  • Loss of Vibration and Proprioception: Especially with posterior column involvement.
  • Lhermitte's Sign: Electric shock-like sensation running down the spine and into the limbs, typically with neck flexion (highly suggestive of posterior column pathology in the cervical cord).
• Autonomic Dysfunction:
  • Bowel/Bladder Dysfunction: Urinary urgency, frequency, incontinence, retention; constipation, fecal incontinence.
  • Sexual Dysfunction: Erectile dysfunction, anorgasmia.

Early Signs

• Subtle gait unsteadiness, feeling of "walking on sponges."
• Fine motor difficulties, especially with intricate tasks (e.g., buttoning shirts, handwriting changes, dropping objects).
• Mild numbness or paresthesias in feet or hands.
• Increased deep tendon reflexes without obvious weakness.
• Changes in bowel/bladder habits (e.g., mild urgency).

Advanced Signs

• Severe paresis or paralysis (paraparesis, quadriparesis), often with significant spasticity.
• Profound sensory loss, often with a clear sensory level.
• Severe neurogenic bladder and bowel, leading to recurrent UTIs, constipation, or incontinence.
• Chronic neuropathic pain.
• Muscle atrophy and contractures (if long-standing or associated with anterior horn cell involvement).
• Autonomic dysreflexia (in high thoracic/cervical lesions, especially in SCI).

Atypical Presentations

• Pure Sensory Myelopathy: Predominant or exclusive sensory symptoms, often with a vague sensory level.
• Painful Myelopathy: Severe focal or radicular pain preceding or accompanying neurological deficits (e.g., spinal tumor, epidural abscess, acute disc herniation).
• Brown-Séquard Syndrome: Hemisection of the spinal cord (rare in pure form), resulting in ipsilateral motor weakness and proprioceptive loss, and contralateral pain and temperature loss below the lesion.
• Man-in-a-Barrel Syndrome: Bilateral brachial paresis with intact cranial nerves and legs, typically due to watershed infarct in the cervical cord.

Physical Examination

Inspection

• Gait: Observe for spastic (stiff, scissoring, circumduction) or ataxic (wide-based, unsteady) gait. Tandem gait may be impaired.
• Muscle Bulk: Look for muscle atrophy (especially in hands with cervical myelopathy, or if anterior horn cells are involved).
• Skin: Evidence of trauma, skin breakdown (pressure sores), or signs of underlying systemic disease.

Palpation

• Spinal Tenderness: While myelopathy itself often does not cause tenderness, local tenderness may point to a specific etiology (e.g., vertebral fracture, infection, tumor).
• Muscle Tone: Assess for spasticity (velocity-dependent resistance to passive movement), rigidity, or hypotonia.

Special Tests

A thorough neurological examination is crucial to localize the lesion and identify the extent of involvement.

• Motor Examination:
  • Strength Testing: Assess strength in all four limbs (e.g., using MRC scale 0-5).
  • Deep Tendon Reflexes (DTRs): Hyperreflexia, clonus (sustained rhythmic contractions in response to stretch) below the lesion are hallmarks of upper motor neuron (UMN) dysfunction. Hyporeflexia or areflexia may be present at the level of the lesion due to lower motor neuron (LMN) involvement (e.g., anterior horn cell damage, severe nerve root compression).
  • Pathological Reflexes:
    • Babinski Sign: Dorsiflexion of the great toe and fanning of other toes on plantar stimulation (UMN lesion).
    • Hoffman Sign: Flexion and adduction of the thumb with flexion of the index or middle finger when flicking the distal phalanx of the middle finger (UMN lesion, often highly sensitive for cervical myelopathy).
    • Inverted Radial Reflex: Biceps or finger flexion instead of brachioradialis contraction when tapping the radial styloid.
• Sensory Examination:
  • Pinprick and Temperature: Test symmetrically, moving from abnormal to normal areas to identify a sensory level (spinothalamic tract).
  • Light Touch: Test with cotton wool.
  • Vibration and Proprioception: Test with tuning fork (128 Hz) and joint position sense, particularly in toes and fingers (posterior columns).
• Coordination:
  • Finger-to-Nose Test: May show dysmetria.
  • Rapid Alternating Movements: May be impaired.
  • Romberg Test: Worsening of balance with eyes closed suggests proprioceptive loss (posterior column dysfunction).
• Autonomic/Sphincter Function:
  • Anal Tone: Assess anal sphincter tone (decreased in conus medullaris or cauda equina syndrome).
  • Bulbocavernosus Reflex: Elicited by squeezing the glans penis or clitoris and observing anal sphincter contraction (tests S2-S4 reflex arc).

Diagnostic Approach

History Taking

Key Questions * Onset and Progression: Is it acute (minutes-hours), subacute (days-weeks), or chronic (months-years)? Is it progressive, relapsing-remitting, or static? * Nature of Symptoms: * Motor: Weakness, stiffness, gait difficulty, falls, fine motor problems (e.g., buttoning, writing). * Sensory: Numbness, tingling, burning, pain, band-like sensations, Lhermitte's sign. * Autonomic: Bladder urgency/frequency, incontinence/retention, constipation, erectile dysfunction. * Associated Symptoms: * Pain: Location, character, radiation, aggravating/alleviating factors. * Constitutional Symptoms: Fever, chills, night sweats, weight loss (suggestive of infection, malignancy). * Trauma: Recent or past spinal injury. * Systemic Illnesses: Autoimmune diseases (MS, lupus), diabetes, cardiovascular disease, malignancy. * Medications/Substances: Immunosuppressants, chemotherapy, illicit drugs, vitamin supplements. * Travel History: Exposure to infectious agents. * Dietary Habits: Strict veganism (risk of B12 deficiency). * Past Medical History: Prior spinal surgeries, radiation therapy, history of cancer, autoimmune disorders.

Red Flags * Acute or Rapidly Progressive Weakness: Particularly if ascending or associated with respiratory compromise. * Fever, Chills, Night Sweats: Suggestive of infection (e.g., epidural abscess). * Severe Back or Neck Pain: Especially if new onset, unrelieved by rest, or associated with neurological deficit. * Recent Trauma: High suspicion for spinal cord injury. * Constitutional Symptoms (Unexplained Weight Loss, Fatigue): Concern for malignancy. * Bladder or Bowel Incontinence/Retention: Especially acute onset, indicative of severe cord or cauda equina involvement. * Saddle Anesthesia: Perineal numbness, a key symptom of cauda equina syndrome. * Immunocompromised Status: Increased risk for opportunistic infections.

Laboratory Tests

Laboratory tests are guided by the differential diagnosis suggested by history and physical examination.

First-Line (Initial Diagnostic Tests)

• Complete Blood Count (CBC): Anemia (B12 deficiency), leukocytosis (infection/inflammation).
• Erythrocyte Sedimentation Rate (ESR) and C-Reactive Protein (CRP): Elevated in inflammatory or infectious processes.
• Metabolic Panel: Electrolytes, renal/liver function.
• Vitamin B12 and Methylmalonic Acid (MMA) levels: To evaluate for B12 deficiency. MMA is a more sensitive indicator.
• Syphilis Serology (RPR/VDRL, FTA-ABS): Neurosyphilis.
• HIV Test: HIV-associated myelopathy.
• Copper and Zinc Levels: If copper deficiency is suspected (e.g., from excessive zinc intake or malabsorption).

Confirmatory (Definitive Diagnostic Tests)

• Cerebrospinal Fluid (CSF) Analysis (via Lumbar Puncture):
  • Cell count and differential: Pleocytosis (inflammatory/infectious).
  • Protein: Elevated in many myelopathies (inflammation, tumor, infection).
  • Glucose: Decreased in bacterial meningitis/some tumors.
  • IgG Index and Oligoclonal Bands (OCBs): Suggestive of MS or other inflammatory demyelinating diseases.
  • Specific Antibodies: Anti-AQP4 (NMOSD), Anti-MOG (MOGAD).
  • Infectious Studies: VDRL, viral PCRs (HSV, VZV, CMV, enteroviruses), bacterial cultures, cryptococcal antigen, acid-fast bacilli (AFB) stain/culture.
• Autoimmune Panel: ANA, anti-dsDNA, ENA panel (if systemic autoimmune disease suspected).
• Paraneoplastic Antibodies: If malignancy is suspected and other causes ruled out.
• Genetic Testing: For suspected hereditary myelopathies (e.g., hereditary spastic paraplegia).

Monitoring

• Repeat Inflammatory Markers (ESR/CRP): To assess response to treatment in inflammatory conditions.
• Vitamin Levels: To monitor adequacy of replacement therapy.
• CSF Analysis: May be repeated to assess treatment response or rule out persistent infection.
• Disease-specific biomarkers: As applicable (e.g., NMO-IgG titers).

Imaging

Imaging is paramount in the diagnostic workup of myelopathy to identify the lesion and its etiology.

Recommended

• Magnetic Resonance Imaging (MRI) of the Spinal Cord (entire spine if necessary) with and without Gadolinium Contrast:
  • Rationale: The gold standard for evaluating the spinal cord and surrounding structures. It provides excellent soft tissue contrast, allowing visualization of:
    • Compressive lesions: Disc herniations, osteophytes, tumors (intramedullary, intradural-extramedullary, extradural), epidural hematomas/abscesses.
    • Inflammatory/demyelinating lesions: Cord edema, T2 hyperintense lesions, gadolinium enhancement (indicating blood-brain barrier disruption/active inflammation) in MS, NMOSD, transverse myelitis.
    • Ischemic lesions: Restricted diffusion on DWI, T2 hyperintensity.
    • Syringomyelia/Hydromyelia: Fluid-filled cavities within the cord.
  • Technique: T1-weighted, T2-weighted, STIR (short tau inversion recovery) or fat-saturated T2 sequences are crucial. Post-gadolinium T1 sequences are essential to identify active inflammation, tumors, or infections. Imaging should include the entire relevant segment of the spinal cord (cervical, thoracic, lumbar) and potentially the brain (e.g., to look for MS lesions).

Advanced

• CT Myelography:
  • Rationale: Performed when MRI is contraindicated (e.g., pacemakers, certain metal implants) or when bony detail is particularly important (e.g., complex fractures, spinal stenosis, ossification of the posterior longitudinal ligament (OPLL)). Contrast is injected into the subarachnoid space, followed by CT imaging to outline the spinal cord and nerve roots.
• Computed Tomography Angiography (CTA) or Magnetic Resonance Angiography (MRA) of the Spinal Cord:
  • Rationale: Considered if a vascular etiology (e.g., dural arteriovenous fistula, vascular malformation, spinal cord infarction) is suspected but not definitively identified on routine MRI. Spinal angiography (digital subtraction angiography) is the gold standard for vascular malformations.
• Somatosensory Evoked Potentials (SSEPs) / Motor Evoked Potentials (MEPs):
  • Rationale: Electrophysiological studies that can assess the integrity of sensory and motor pathways in the spinal cord. They can confirm myelopathy, localize a lesion (especially in non-compressive causes), and assess severity or monitor progression, though they are less useful for initial diagnosis than MRI.

Management

Management of myelopathy is highly dependent on the underlying cause, severity, and acuity.

Acute Management

Immediate (First-hour interventions)

• Airway, Breathing, Circulation (ABC): Especially critical in high cervical cord lesions which can compromise respiratory drive. Endotracheal intubation may be required.
• Spinal Immobilization: For suspected traumatic spinal cord injury (e.g., with a rigid cervical collar, backboard) until imaging rules out unstable fractures.
• High-Dose Glucocorticoids:
  • For Acute Transverse Myelitis (ATM): Methylprednisolone 1000 mg IV daily for 3-5 days.
  • For Acute Spinal Cord Injury (SCI): While historically used, the use of high-dose corticosteroids (e.g., methylprednisolone 30 mg/kg bolus, then 5.4 mg/kg/hr for 23-47 hours) for acute traumatic SCI is controversial and no longer routinely recommended due to marginal benefit and increased risk of complications (e.g., sepsis, pneumonia, GI bleeding).
  • For Acute Compressive Myelopathy (e.g., metastatic epidural cord compression): Dexamethasone 10-16 mg IV bolus, then 4 mg IV q6h or 8 mg IV BID to reduce vasogenic edema and provide temporary relief while definitive treatment is planned.

Stabilization (Early management priorities)

• Urgent Neurosurgical/Orthopedic Consultation: For acute compressive myelopathy (e.g., acute disc herniation with severe cord compression, epidural abscess, spinal tumor, traumatic SCI with instability). Timely decompression is crucial to prevent irreversible damage.
• Pain Management: Opioids, NSAIDs as appropriate.
• Bladder Management: Indwelling urinary catheter for urinary retention.
• DVT Prophylaxis: Low molecular weight heparin (LMWH) or unfractionated heparin, along with sequential compression devices, to prevent venous thromboembolism in immobile patients.
  • LMWH: Enoxaparin 30 mg SC BID or 40 mg SC daily.
• Gastric Stress Ulcer Prophylaxis: Proton pump inhibitors (PPIs) or H2 blockers, especially if on corticosteroids.

Emergency (Crisis management)

• Acute Spinal Cord Compression: This is a neurosurgical emergency. Surgical decompression (laminectomy, discectomy, corpectomy, tumor resection) is often required as rapidly as possible, especially within 24-48 hours, for optimal outcomes.
• Epidural Abscess: Urgent surgical drainage and prolonged antibiotic therapy.
• Spinal Cord Infarction: No specific acute treatment, focus on supportive care and optimizing cardiovascular status.
• Autoimmune Myelopathies (e.g., NMOSD flare): Plasma exchange (PLEX) or intravenous immunoglobulin (IVIG) may be considered if corticosteroids are insufficient.

Chronic Management

Pharmacological

• Spasticity:
  • First-line oral: Baclofen (start 5-10 mg TID, titrate to 20 mg QID, max 80 mg/day), Tizanidine (start 2 mg TID, titrate to 8 mg QID, max 36 mg/day).
  • Second-line oral: Dantrolene (25-100 mg BID-QID, max 400 mg/day), Gabapentin (300-1200 mg TID).
  • Refractory: Intrathecal baclofen pump, botulinum toxin injections for focal spasticity.
• Neuropathic Pain:
  • First-line: Gabapentin (start 300 mg daily/BID, titrate to 900-3600 mg/day in divided doses), Pregabalin (start 75 mg BID, titrate to 150-300 mg BID).
  • Second-line: Tricyclic antidepressants (TCAs) like Amitriptyline (start 10-25 mg HS, titrate to 50-150 mg HS), SNRIs like Duloxetine (30-60 mg daily).
  • Topical: Lidocaine patches, capsaicin cream.
• Bladder Dysfunction:
  • Overactive bladder: Anticholinergics (Oxybutynin, Tolterodine), Beta-3 agonists (Mirabegron).
  • Urinary retention: Alpha-blockers (Tamsulosin) for sphincter relaxation, intermittent catheterization.
• Bowel Dysfunction: Stool softeners, laxatives, fiber supplements, bowel regimens.
• Disease-Modifying Therapies (DMTs): For inflammatory myelopathies like MS or NMOSD. These are specific to the underlying condition (e.g., interferons, glatiramer acetate, natalizumab, ocrelizumab for MS; rituximab, eculizumab, satralizumab for NMOSD).

Non-pharmacological

• Physical Therapy: To maintain muscle strength and range of motion, improve gait, balance, and transfer skills.
• Occupational Therapy: To adapt daily activities, provide assistive devices (e.g., walkers, wheelchairs, orthotics), and modify home/work environments.
• Speech Therapy: If bulbar involvement.
• Bladder/Bowel Programs: Regular voiding schedules, dietary modifications.
• Psychological Support: Counseling, support groups to address depression, anxiety, and coping with chronic disability.
• Sexual Counseling: For sexual dysfunction.
• Nutrition Counseling: To optimize overall health and prevent deficiencies.

Monitoring

• Regular Neurological Assessments: To monitor disease progression, treatment efficacy, and detect new complications.
• Functional Assessments: Using scales like the Modified Japanese Orthopedic Association (mJOA) score for CSM, or specific SCI scales.
• Imaging: Repeat MRI may be indicated to monitor disease activity (e.g., in MS, tumors) or progression of compressive lesions.
• Laboratory Tests: As appropriate for specific conditions (e.g., vitamin levels, inflammatory markers, therapeutic drug monitoring for DMTs).
• Bone Density Scans: For patients on chronic corticosteroids or with prolonged immobility.

Treatment Algorithms

First-Line

• Identify and Address Underlying Cause:
  • Acute Compressive Myelopathy (e.g., severe disc herniation, tumor, epidural abscess): Urgent surgical decompression (laminectomy, discectomy, corpectomy) + high-dose corticosteroids (for edema).
  • Acute Transverse Myelitis/NMOSD: High-dose IV methylprednisolone (1g IV daily for 3-5 days).
  • Vitamin B12 Deficiency: Vitamin B12 replacement (e.g., Cyanocobalamin 1000 mcg IM daily for 1 week, then weekly for 1 month, then monthly for life).
  • Infections (e.g., HIV, syphilis, Lyme): Appropriate antimicrobial therapy.
  • Traumatic SCI: Stabilization of spine, supportive care, rehabilitation.
• Symptomatic Management: Initiate therapies for spasticity, neuropathic pain, bladder/bowel dysfunction.

Second-Line

• Inadequate Response to First-Line:
  • Inflammatory/Autoimmune: If corticosteroids are ineffective or contraindicated, consider plasma exchange (PLEX) (5-7 exchanges over 7-14 days) or intravenous immunoglobulin (IVIG) (0.4 g/kg/day for 5 days).
  • Chronic Compressive (e.g., CSM with mild-moderate symptoms): Continued physical therapy, cervical collar (short-term), NSAIDs, neuropathic pain medications. Surgical decompression if conservative management fails or symptoms worsen.
• Pharmacological Adjustments: Titrate dosages, switch to alternative agents for spasticity or pain.

Refractory Cases

• Intrathecal Baclofen Pump: For severe, intractable spasticity.
• Botulinum Toxin Injections: For focal spasticity.
• Advanced Pain Management: Referral to pain clinic for interventional procedures (e.g., spinal cord stimulation).
• Immunosuppressive Agents: For refractory autoimmune myelopathies (e.g., cyclophosphamide, azathioprine, rituximab, mycophenolate mofetil).
• Multidisciplinary Team Approach: Involving neurologists, neurosurgeons, rehabilitation specialists, physical therapists, occupational therapists, pain specialists, urologists, gastroenterologists, and social workers.
• Consider Experimental Therapies/Clinical Trials: For patients who have exhausted standard treatments.

Complications

Common

• Spasticity: Can lead to muscle contractures, pain, and difficulty with mobility.
• Neuropathic Pain: Chronic, often debilitating pain below the level of the lesion.
• Bladder and Bowel Dysfunction: Leading to recurrent urinary tract infections (UTIs), kidney stones, hydronephrosis, constipation, or fecal incontinence.
• Sexual Dysfunction: Impotence in men, anorgasmia in women.
• Muscle Weakness and Atrophy: Can lead to decreased mobility and functional independence.
• Pressure Ulcers (Bedsores): Due to immobility and sensory loss.
• Depression and Anxiety: Psychological impact of chronic illness and disability.

Serious

• Respiratory Failure: Especially with high cervical lesions (C1-C5) affecting the phrenic nerve.
• Autonomic Dysreflexia: A potentially life-threatening syndrome in patients with SCI above T6, characterized by sudden severe hypertension, bradycardia, headache, sweating, and piloerection in response to noxious stimuli below the level of injury (e.g., full bladder, bowel impaction).
• Deep Vein Thrombosis (DVT) and Pulmonary Embolism (PE): High risk due to immobility and hypercoagulability.
• Sepsis: From UTIs, pneumonia, or pressure ulcers.
• Progressive Neurological Deficit: Due to ongoing compression, inflammation, or disease progression.
• Syringomyelia: Formation of fluid-filled cavities within the spinal cord, which can expand and cause further neurological deficits.

Long-term

• Chronic Disability: Varying degrees of motor, sensory, and autonomic impairment, impacting quality of life and independence.
• Contractures and Deformities: Due to prolonged spasticity and immobility.
• Osteoporosis: Due to immobility and sometimes chronic corticosteroid use.
• Increased Cardiovascular Risk: Due to inactivity and autonomic dysfunction.
• Psychosocial Impact: Job loss, relationship strain, social isolation.

Prognosis

Prognosis for myelopathy is highly variable and depends on numerous factors.

Factors

• Etiology:
  • Better Prognosis: Treatable causes like vitamin B12 deficiency (if diagnosed early), acute inflammatory myelopathies (e.g., some cases of transverse myelitis with prompt treatment), acute compressive lesions (if rapid and complete decompression).
  • Worse Prognosis: Rapidly progressive or severe traumatic injuries, aggressive tumors, progressive degenerative conditions, and some forms of chronic inflammatory myelopathy (e.g., severe NMOSD).
• Severity at Presentation: Patients with more severe initial neurological deficits tend to have poorer outcomes.
• Duration of Symptoms: Shorter duration of symptoms prior to diagnosis and treatment is generally associated with better recovery, especially for compressive lesions.
• Age: Younger patients often have better recovery potential than older adults.
• Extent of Spinal Cord Damage: Measured by imaging (MRI showing atrophy or extensive signal change) and electrophysiology (SSEPs, MEPs).
• Response to Treatment: Early and robust response to specific therapies (e.g., corticosteroids for TM, surgery for compression).
• Rehabilitation Efforts: Intensive and sustained rehabilitation can significantly improve functional outcomes.
• Comorbidities: Presence of other health conditions (e.g., diabetes, cardiovascular disease) can negatively impact recovery and increase complication risk.

Survival

• Survival rates vary widely. For instance, in traumatic SCI, 1-year survival rates are high (90-95%), but long-term mortality is higher than the general population due to complications.
• Conditions like NMOSD can have significant mortality if severe relapses are not treated promptly.
• Myelopathy due to malignancy carries a prognosis largely dependent on the underlying cancer.
• Many forms of chronic myelopathy (e.g., CSM) are not directly life-threatening but cause significant morbidity.

Quality of Life

• Myelopathy can significantly impair quality of life due to motor, sensory, and autonomic deficits, impacting independence, work, social activities, and mental health.
• Functional outcomes range from complete recovery (rare) to severe, permanent disability requiring extensive assistance.
• Psychosocial support, adaptive equipment, and comprehensive rehabilitation are crucial for maximizing functional independence and improving quality of life.

Prevention

Primary (Preventing initial occurrence)

• Injury Prevention: Safe driving practices, use of safety equipment in sports, fall prevention strategies (especially in the elderly).
• Nutritional Sufficiency: Ensuring adequate intake of essential vitamins (e.g., vitamin B12 through diet or supplementation for at-risk individuals).
• Management of Systemic Diseases: Strict control of hypertension, diabetes, and hyperlipidemia to reduce the risk of vascular myelopathy.
• Lifestyle Modifications: Regular exercise, maintaining a healthy weight, and proper ergonomics to minimize stress on the spine.
• Vaccination: Against preventable infections that can cause myelopathy (e.g., polio, measles).

Secondary (Early detection and intervention)

• Early Diagnosis of Spinal Stenosis: Regular check-ups and imaging if symptomatic.
• Monitoring and Treatment of Autoimmune Diseases: Proactive management of conditions like MS, NMOSD, and lupus to prevent or reduce the frequency and severity of myelopathic attacks.
• Screening for Nutritional Deficiencies: In at-risk populations (e.g., post-gastrectomy, strict vegans).
• Prompt Evaluation of Neurological Symptoms: Any new or worsening neurological symptoms suggestive of myelopathy should prompt urgent medical evaluation and imaging.

Tertiary (Preventing complications)

• Comprehensive Rehabilitation: Physical, occupational, and speech therapy to optimize functional recovery and prevent secondary complications like contractures.
• Regular Monitoring and Follow-up: To detect and manage complications such as UTIs, pressure sores, spasticity, and pain.
• Patient and Caregiver Education: On bladder/bowel management, skin care, medication adherence, and recognizing signs of complications (e.g., autonomic dysreflexia).
• Adaptive Equipment: Provision of wheelchairs, braces, and other assistive devices to maintain mobility and independence.
• Psychological Support: To address depression, anxiety, and facilitate adaptation to disability.

Special Populations

Pediatric

• Etiologies: Differ from adults; include congenital malformations (e.g., tethered cord syndrome, spina bifida, Chiari malformation), acute disseminated encephalomyelitis (ADEM), acute flaccid myelitis (often post-viral, e.g., enterovirus D68), genetic disorders, and some tumors.
• Clinical Presentation: May be less specific. Developmental delay, gait abnormalities, changes in bladder/bowel control. Young children may not verbalize sensory symptoms.
• Diagnosis: Imaging (MRI) is essential, often requiring sedation. CSF analysis, genetic testing.
• Management: Often involves a multidisciplinary team including pediatric neurologists, neurosurgeons, and rehabilitation specialists. Specific treatments depend on the etiology.

Geriatric

• Etiologies: Higher incidence of degenerative causes (CSM, OPLL), vascular myelopathy, and malignancy. Polypharmacy and multiple comorbidities are common.
• Clinical Presentation: Symptoms can be insidious and attributed to "old age." Gait disturbance is a common early sign. Cognitive impairment may complicate history taking.
• Diagnosis: MRI with careful consideration of renal function for contrast. Need to differentiate from peripheral neuropathy, normal pressure hydrocephalus, or cerebrovascular disease.
• Management: Conservative management may be favored due to surgical risks, but timely surgery for significant compression can still improve outcomes. Careful consideration of drug interactions for pharmacological treatments. Rehabilitation may be slower.

Pregnancy

• Diagnosis: MRI is the preferred imaging modality; generally considered safe, but gadolinium contrast is usually avoided, especially in the first trimester, unless absolutely necessary.
• Etiologies: Can include gestational disc herniations, pre-existing conditions like MS or NMOSD (pregnancy can influence disease activity), or rare complications like spinal epidural hematoma.
• Management: Medication choices must consider fetal safety. Corticosteroids may be used with caution. Surgical intervention, if needed, should be coordinated with obstetrics. Careful monitoring of disease activity (e.g., MS relapse rate often decreases in the third trimester but increases postpartum).

Comorbidities

• Diabetes: Increased risk of vascular myelopathy, peripheral neuropathy can complicate diagnosis, impaired wound healing.
• Cardiovascular Disease: Risk for spinal cord infarction, impacts surgical risk.
• Renal/Hepatic Dysfunction: Requires dose adjustments for many medications (e.g., baclofen, gabapentin). Contrast nephropathy risk with gadolinium (though group II gadolinium agents have low risk for patients with normal renal function, caution still exercised in severe renal impairment).
• Immunosuppression: Increased risk of opportunistic infections causing myelopathy.

Clinical Pearls

Diagnostic

• Think Myelopathy: In any patient presenting with bilateral or asymmetric weakness/sensory changes in the limbs, gait disturbance, and/or bladder/bowel dysfunction, especially with upper motor neuron signs (hyperreflexia, spasticity, Babinski).
• Sensory Level is Key: A definite sensory level on examination is highly specific for a spinal cord lesion. If present, it helps localize the lesion.
• Always Image the Entire Spine: Especially with non-compressive myelopathies, as lesions can be multifocal or at an unexpected level. If brain lesions are suspected (e.g., MS), include brain MRI.
• Don't Mistake Radiculopathy for Myelopathy: Radiculopathy causes LMN signs, dermatomal/myotomal pain/weakness; myelopathy causes UMN signs and often involves long tracts. Overlapping symptoms can occur (e.g., cervical myelopathy can present with radicular arm pain).
• CSF Analysis for Non-Compressive Myelopathy: Lumbar puncture is often critical for diagnosis of inflammatory, infectious, or autoimmune myelopathies when imaging is non-diagnostic or only shows non-specific changes.

Treatment

• Time is Spine: For acute compressive myelopathy, timely surgical decompression is paramount to prevent permanent neurological deficits.
• Multidisciplinary Approach: Chronic myelopathy benefits significantly from a team approach involving neurologists, neurosurgeons, rehabilitation specialists, physical/occupational therapists, and supportive care providers.
• Prophylaxis is Crucial: For immobile patients, aggressive DVT prophylaxis and pressure ulcer prevention are essential.
• Educate Patients: On bladder/bowel management, skin care, medication adherence, and recognizing warning signs (e.g., autonomic dysreflexia).

Pitfalls

• Misdiagnosis: Confusing myelopathy with peripheral neuropathy, brain lesions (e.g., stroke, MS with only brain lesions), or psychogenic disorders.
• Delay in Diagnosis of Treatable Causes: Especially for conditions like B12 deficiency, epidural abscess, or acute spinal cord compression, where delayed treatment leads to worse outcomes.
• Incomplete Imaging: Failing to image the entire spinal cord, potentially missing lesions at other levels or concomitant brain lesions.
• Overlooking Autonomic Dysfunction: Not actively assessing or addressing bladder, bowel, and sexual dysfunction can significantly impact patient quality of life and lead to complications.
• Ignoring Red Flags: Dismissing fever, constitutional symptoms, or severe pain in a patient with neurological deficits.

Recent Updates

Guidelines

• Cervical Spondylotic Myelopathy (CSM): Updated guidelines from the American Association of Neurological Surgeons (AANS) and Congress of Neurological Surgeons (CNS) (e.g., 2017) recommend surgical intervention over nonoperative treatment for moderate-to-severe CSM. For mild CSM, both conservative management and surgery are options, but close monitoring is required.
• Neuromyelitis Optica Spectrum Disorder (NMOSD): International consensus diagnostic criteria (2015) and treatment guidelines (e.g., 2021 ECTRIMS/EAN guidelines) emphasize the importance of identifying AQP4-IgG status to guide diagnosis and highly effective immunotherapies (e.g., eculizumab, satralizumab, inebilizumab) now available.
• Multiple Sclerosis (MS): Updated McDonald criteria (2017) for MS diagnosis, and numerous new disease-modifying therapies (DMTs) are approved, some with high efficacy for spinal cord involvement.

Evidence

• Advanced Imaging Techniques: Diffusion tensor imaging (DTI) and functional MRI are emerging as research tools to quantify microstructural damage and functional changes in myelopathy, potentially offering more sensitive measures of disease progression and treatment response.
• Biomarkers: Research is ongoing for novel CSF and serum biomarkers for specific myelopathies (e.g., neurofilament light chain (NfL) as a marker of axonal damage in various inflammatory/neurodegenerative conditions).
• Regenerative Therapies: Stem cell therapies and other regenerative medicine approaches are under investigation, particularly for chronic spinal cord injury, but are largely experimental and not standard of care.
• Targeted Immunotherapies: Development of increasingly specific immunomodulatory drugs for autoimmune and inflammatory myelopathies continues to improve outcomes.

Controversies

• Timing of Surgery for CSM: While generally agreed that earlier intervention is better for moderate-to-severe CSM, the optimal timing for mild CSM and the role of prophylactic surgery for asymptomatic spinal cord compression remain debated.
• Role of Corticosteroids in Traumatic SCI: Despite past widespread use, current evidence suggests limited benefit and potential harm, leading to a shift away from routine high-dose methylprednisolone.
• Management of Acute Spinal Cord Infarction: Given its rarity and lack of large trials, management strategies are largely extrapolated from cerebral ischemia, with no proven effective acute specific treatment.

Key References

Guidelines

• AANS/CNS Guidelines for the Management of Cervical Spondylotic Myelopathy: Published in various neurological and neurosurgical journals (e.g., Spine, Neurosurgery).
• European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS) / European Academy of Neurology (EAN) Guidelines: For the management of Multiple Sclerosis.
• International Consensus Diagnostic Criteria for Neuromyelitis Optica Spectrum Disorders (NMOSD): Wingerchuk DM et al., Neurology 2015.
• American Academy of Neurology (AAN) Guidelines: Various guidelines for specific neurological conditions.

Studies

• Subacute Combined Degeneration: Landmark studies on vitamin B12 deficiency and its neurological manifestations.
• Transverse Myelitis Consortium Working Group: Publications on diagnostic criteria and outcome measures for ATM.
• Clinical Trials on Disease-Modifying Therapies: For MS and NMOSD (e.g., NEJM, Lancet Neurology for studies on natalizumab, ocrelizumab, eculizumab, satralizumab).

Reviews

• UpToDate: Comprehensive, regularly updated reviews on all myelopathy etiologies.
• Harrison's Principles of Internal Medicine / Bradley's Neurology in Clinical Practice: Standard medical and neurology textbooks.
• Seminars in Neurology, Current Opinion in Neurology, Lancet Neurology: Journals frequently publishing comprehensive review articles on myelopathy and related disorders.